← Back to Screener
Trevi Therapeutics, Inc. Common Stock (TRVI)
Price$13.33
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-6.86%
Price vs S&P 500 (4W)-8.06%
VGM Score71.19
Market Capitalization$1.89B
All Metrics
Book Value / Share (Quarterly)$1.34
P/TBV (Annual)1.67x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.35
Price vs S&P 500 (YTD)-1.69%
EPS (TTM)$-0.32
10-Day Avg Trading Volume0.95M
EPS Excl Extra (TTM)$-0.32
EPS (Annual)$-0.32
ROI (Annual)-23.33%
Cash / Share (Quarterly)$1.34
ROA (Last FY)-22.10%
EBITD / Share (TTM)$-0.37
ROE (5Y Avg)-66.44%
Cash Flow / Share (Annual)$-0.33
P/B Ratio11.00x
P/B Ratio (Quarterly)8.90x
Net Income / Employee (Annual)$-1,257,600
Net Interest Coverage (TTM)-29.59x
ROA (TTM)-23.37%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)19.66x
Quick Ratio (Quarterly)24.44x
3-Month Avg Trading Volume1.42M
52-Week Price Return97.77%
Tangible BV / Share (Quarterly)$1.79
52-Week High$16.12
EPS Excl Extra (Annual)$-0.32
CapEx CAGR (5Y)-16.74%
Tangible BV CAGR (5Y)48.70%
26-Week Price Return1.06%
Quick Ratio (Annual)19.53x
13-Week Price Return1.91%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)24.75x
Enterprise Value$1.87B
Book Value / Share Growth (5Y)-0.65%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.47
3-Month Return Std Dev54.19%
Net Income / Employee (TTM)$-1,341,500
ROE (Last FY)-23.33%
Net Interest Coverage (Annual)-27.08x
EPS Basic Excl Extra (Annual)$-0.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.32
ROI (TTM)-24.53%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.79
Price vs S&P 500 (52W)73.41%
Year-to-Date Return6.47%
5-Day Price Return-4.44%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-41.93%
Month-to-Date Return-5.73%
Cash Flow / Share (TTM)$-0.57
EBITD / Share (Annual)$-0.36
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-47.72%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)1.67x
P/B Ratio (Annual)8.76x
Book Value / Share (Annual)$1.43
Price vs S&P 500 (13W)-6.34%
Beta1.06x
ROE (TTM)-24.53%
52-Week Low$5.41
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.09est. -0.08
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.28
4.28
4.28
4.28
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TRVITrevi Therapeutics, Inc. Common Stock | — | — | B | $13.33 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release formulation of nalbuphine. The company is advancing Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis and other chronic cough indications, as well as for prurigo nodularis. Haduvio represents a novel therapeutic approach for these underserved patient populations.